Overview

Study of Oral PG-116800 Following a Heart Attack

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to test whether a possible new drug (called PG-116800) can prevent some of the damage to heart muscle in patients who have had a heart attack. The study will also supply information regarding possible uses of this compound in cardiovascular disease.
Phase:
Phase 2
Details
Lead Sponsor:
Procter and Gamble